Cargando…

In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by dementia, excessive acetylcholinesterase (AChE) activity, formation of neurotoxic amyloid plaque, and tau protein aggregation. Based on literature survey, we have shortlisted three important target proteins (AChE, COX2, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasool, Mahmood, Malik, Arif, Waquar, Sulayman, Tul-Ain, Qura, Jafar, Tassadaq H., Rasool, Rabia, Kalsoom, Aasia, Ghafoor, Muhammad A., Sehgal, Sheikh A., Gauthaman, Kalamegam, Naseer, Muhammad I., Al-Qahtani, Mohammed H., Pushparaj, Peter N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085546/
https://www.ncbi.nlm.nih.gov/pubmed/30123124
http://dx.doi.org/10.3389/fphar.2018.00730
_version_ 1783346352596451328
author Rasool, Mahmood
Malik, Arif
Waquar, Sulayman
Tul-Ain, Qura
Jafar, Tassadaq H.
Rasool, Rabia
Kalsoom, Aasia
Ghafoor, Muhammad A.
Sehgal, Sheikh A.
Gauthaman, Kalamegam
Naseer, Muhammad I.
Al-Qahtani, Mohammed H.
Pushparaj, Peter N.
author_facet Rasool, Mahmood
Malik, Arif
Waquar, Sulayman
Tul-Ain, Qura
Jafar, Tassadaq H.
Rasool, Rabia
Kalsoom, Aasia
Ghafoor, Muhammad A.
Sehgal, Sheikh A.
Gauthaman, Kalamegam
Naseer, Muhammad I.
Al-Qahtani, Mohammed H.
Pushparaj, Peter N.
author_sort Rasool, Mahmood
collection PubMed
description Alzheimer's disease (AD) is a neurodegenerative disorder characterized by dementia, excessive acetylcholinesterase (AChE) activity, formation of neurotoxic amyloid plaque, and tau protein aggregation. Based on literature survey, we have shortlisted three important target proteins (AChE, COX2, and MMP8) implicated in the pathogenesis of AD and 20 different phytocompounds for molecular docking experiments with these three target proteins. The 3D-structures of AChE, COX2, and MMP8 were predicted by homology modeling by MODELLER and the threading approach by using ITASSER. Structure evaluations were performed using ERRAT, Verify3D, and Rampage softwares. The results based on molecular docking studies confirmed that there were strong interactions of these phytocompounds with AChE, COX2, and MMP8. The top three compounds namely Albiziasaponin-A, Iso-Orientin, and Salvadorin showed least binding energy and highest binding affinity among all the scrutinized compounds. Post-docking analyses showed the following free energy change for Albiziasaponin-A, Salvadorin, and Iso-Orientin (−9.8 to −15.0 kcal/mol) as compared to FDA approved drugs (donepezil, galantamine, and rivastigmine) for AD (−6.6 to −8.2 Kcal/mol) and interact with similar amino acid residues (Pro-266, Asp-344, Trp-563, Pro-568, Tyr-103, Tyr-155, Trp-317, and Tyr-372) with the target proteins. Furthermore, we have investigated the antioxidant and anticholinesterase activity of these top three phytochemicals namely, Albiziasaponin-A, Iso-Orientin, and Salvadorin in colchicine induced rat model of AD. Sprague Dawley (SD) rat model of AD were developed using bilateral intracerebroventricular (ICV) injection of colchicine (15 μg/rat). After the induction of AD, the rats were subjected to treatment with phytochemicals individually or in combination for 3 weeks. The serum samples were further analyzed for biomarkers such as 8-hydroxydeoxyguanosine (8-OHdG), 4-hydroxynonenal (4-HNE), tumor necrosis factor-alpha (TNF-α), cyclooxygenase-2 (COX-2), matrix metalloproteinase-8 (MMP-8), isoprostanes-2 alpha (isoP-2α), and acetylcholine esterase (AChE) using conventional Enzyme Linked Immunosorbent Assay (ELISA) method. Additionally, the status of lipid peroxidation was estimated calorimetrically by measuring thiobarbituric acid reactive substances (TBARS). Here, we observed a statistically significant reduction (P < 0.05) in the oxidative stress and inflammatory markers in the treatment groups receiving mono and combinational therapies using Albiziasaponin-A, Iso-Orientin, and Salvadorin as compared to colchicine alone group. Besides, the ADMET profiles of these phytocompounds were very promising and, hence, these potential neuroprotective agents may further be taken for preclinical studies either as mono or combinational therapy for AD.
format Online
Article
Text
id pubmed-6085546
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-60855462018-08-17 In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease Rasool, Mahmood Malik, Arif Waquar, Sulayman Tul-Ain, Qura Jafar, Tassadaq H. Rasool, Rabia Kalsoom, Aasia Ghafoor, Muhammad A. Sehgal, Sheikh A. Gauthaman, Kalamegam Naseer, Muhammad I. Al-Qahtani, Mohammed H. Pushparaj, Peter N. Front Pharmacol Pharmacology Alzheimer's disease (AD) is a neurodegenerative disorder characterized by dementia, excessive acetylcholinesterase (AChE) activity, formation of neurotoxic amyloid plaque, and tau protein aggregation. Based on literature survey, we have shortlisted three important target proteins (AChE, COX2, and MMP8) implicated in the pathogenesis of AD and 20 different phytocompounds for molecular docking experiments with these three target proteins. The 3D-structures of AChE, COX2, and MMP8 were predicted by homology modeling by MODELLER and the threading approach by using ITASSER. Structure evaluations were performed using ERRAT, Verify3D, and Rampage softwares. The results based on molecular docking studies confirmed that there were strong interactions of these phytocompounds with AChE, COX2, and MMP8. The top three compounds namely Albiziasaponin-A, Iso-Orientin, and Salvadorin showed least binding energy and highest binding affinity among all the scrutinized compounds. Post-docking analyses showed the following free energy change for Albiziasaponin-A, Salvadorin, and Iso-Orientin (−9.8 to −15.0 kcal/mol) as compared to FDA approved drugs (donepezil, galantamine, and rivastigmine) for AD (−6.6 to −8.2 Kcal/mol) and interact with similar amino acid residues (Pro-266, Asp-344, Trp-563, Pro-568, Tyr-103, Tyr-155, Trp-317, and Tyr-372) with the target proteins. Furthermore, we have investigated the antioxidant and anticholinesterase activity of these top three phytochemicals namely, Albiziasaponin-A, Iso-Orientin, and Salvadorin in colchicine induced rat model of AD. Sprague Dawley (SD) rat model of AD were developed using bilateral intracerebroventricular (ICV) injection of colchicine (15 μg/rat). After the induction of AD, the rats were subjected to treatment with phytochemicals individually or in combination for 3 weeks. The serum samples were further analyzed for biomarkers such as 8-hydroxydeoxyguanosine (8-OHdG), 4-hydroxynonenal (4-HNE), tumor necrosis factor-alpha (TNF-α), cyclooxygenase-2 (COX-2), matrix metalloproteinase-8 (MMP-8), isoprostanes-2 alpha (isoP-2α), and acetylcholine esterase (AChE) using conventional Enzyme Linked Immunosorbent Assay (ELISA) method. Additionally, the status of lipid peroxidation was estimated calorimetrically by measuring thiobarbituric acid reactive substances (TBARS). Here, we observed a statistically significant reduction (P < 0.05) in the oxidative stress and inflammatory markers in the treatment groups receiving mono and combinational therapies using Albiziasaponin-A, Iso-Orientin, and Salvadorin as compared to colchicine alone group. Besides, the ADMET profiles of these phytocompounds were very promising and, hence, these potential neuroprotective agents may further be taken for preclinical studies either as mono or combinational therapy for AD. Frontiers Media S.A. 2018-08-02 /pmc/articles/PMC6085546/ /pubmed/30123124 http://dx.doi.org/10.3389/fphar.2018.00730 Text en Copyright © 2018 Rasool, Malik, Waquar, Tul-Ain, Jafar, Rasool, Kalsoom, Ghafoor, Sehgal, Gauthaman, Naseer, Al-Qahtani and Pushparaj. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Rasool, Mahmood
Malik, Arif
Waquar, Sulayman
Tul-Ain, Qura
Jafar, Tassadaq H.
Rasool, Rabia
Kalsoom, Aasia
Ghafoor, Muhammad A.
Sehgal, Sheikh A.
Gauthaman, Kalamegam
Naseer, Muhammad I.
Al-Qahtani, Mohammed H.
Pushparaj, Peter N.
In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease
title In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease
title_full In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease
title_fullStr In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease
title_full_unstemmed In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease
title_short In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease
title_sort in-silico characterization and in-vivo validation of albiziasaponin-a, iso-orientin, and salvadorin using a rat model of alzheimer's disease
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085546/
https://www.ncbi.nlm.nih.gov/pubmed/30123124
http://dx.doi.org/10.3389/fphar.2018.00730
work_keys_str_mv AT rasoolmahmood insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease
AT malikarif insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease
AT waquarsulayman insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease
AT tulainqura insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease
AT jafartassadaqh insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease
AT rasoolrabia insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease
AT kalsoomaasia insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease
AT ghafoormuhammada insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease
AT sehgalsheikha insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease
AT gauthamankalamegam insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease
AT naseermuhammadi insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease
AT alqahtanimohammedh insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease
AT pushparajpetern insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease